Developing New Monoclonal Antibodies for Aggressive Lymphoma
- 15 August 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (16), 5297-5298
- https://doi.org/10.1158/1078-0432.ccr-04-0922
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993